Evaluating the Efficacy of an Oral Probiotic in Acne Vulgaris
Study Details
The study aimed to assess the effectiveness of an oral probiotic in treating acne vulgaris in patients aged 12 to 30 years. The probiotic used was a capsule containing Lacticaseibacillus rhamnosus (CECT 30031) and the cyanobacterium Arthrospira platensis (BEA_IDA_0074B).
Key Findings
Patients taking the probiotic showed a 50% improvement in the Acne Global Severity Scale, compared to 29.41% in the placebo group. There was a significant reduction in non-inflammatory acne lesions in the probiotic group, as well as a trend towards a reduction in total lesions. Additionally, 42.50% of patients in the probiotic group saw improvement according to the Global Acne Grading System, compared to 20.58% in the placebo group.
Conclusion
The probiotic used in the study was found to be effective and well-tolerated, suggesting its potential as a treatment option for acne vulgaris patients.
Practical Solutions and Value
Enhancing Clinical Practice
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians, helping to extend the benefits of clinical trials into everyday medical practice.
Streamlining Healthcare Operations
In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally. By using AI, clinics can enhance their workflows and improve patient outcomes, reducing paper routines and improving efficiency.
Learn more about how we can help at aidevmd.com.
